Literature DB >> 34628863

Rufomycins or Ilamycins: Naming Clarifications and Definitive Structural Assignments.

Bin Zhou1,2, Prabhakar S Achanta2,3, Gauri Shetye1, Shao-Nong Chen1,2,3, Hyun Lee1,2,4, Ying-Yu Jin5, Jinhua Cheng6, Mi-Jin Lee6, Joo-Won Suh6, Sanghyun Cho1,2, Scott G Franzblau1,2, Guido F Pauli1,2,3, James B McAlpine1,2,3.   

Abstract

Rufomycin and ilamycin are synonymous for the same class of cyclopeptides, currently encompassing 33 structurally characterized isolates and 9 semisynthetic derivatives. Elucidation of new structures prioritized the consolidation of the names and established the structures of four diastereoisomeric rufomycins with a 2-piperidinone, named rufomycins 4-7, including full 1H/13C NMR assignments. The characteristic HSQC cross-peak for the CH-5, the hemiaminal carbon in amino acid #5, allows assignment of the stereocenters C-4 and C-5 within this ring. Semisynthetic derivatives (rufomycinSS 1, 2, and 3) were prepared from a rufomycins 4 and 6 mixture to validate the structural assignments. Based on the X-ray crystal structures of rufomycins 2 and 4, considering the NMR differences of rufomycins 7 vs 4-6 compared to rufomycinSS 1 vs 2 and 3, and taking into account that two major conformers, A and B, occur in both rufomycinSS 2 and 3, structural modeling was pursued. Collectively, this paper discusses the NMR spectroscopic differences of the stereoisomers and their possible 3D conformers and correlates these with the anti-Mycobacterium tuberculosis activity. In addition, a look at the history prioritizes names and numbering schemes for this group of antibiotics and leads to consolidated nomenclature for all currently known members, natural and semisynthetic derivatives, and serves to accommodate future discoveries.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34628863      PMCID: PMC8865217          DOI: 10.1021/acs.jnatprod.1c00198

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  21 in total

1.  A NEW AMINO ACID FROM ILAMYCIN B1 AND THE STRUCTURE OF ILAMYCIN B1.

Authors:  T TAKITA; H NAGANAWA; K MAEDA; H UMEZAWA
Journal:  J Antibiot (Tokyo)       Date:  1964-03       Impact factor: 2.649

2.  FURTHER STUDIES ON THE TRYPTOPHAN-PARTS OF ILAMYCINS.

Authors:  T TAKITA; H NAGANAWA; K MAEDA; H UMEZAWA
Journal:  J Antibiot (Tokyo)       Date:  1964-11       Impact factor: 2.649

3.  New antibiotics, ilamycins.

Authors:  T TAKITA; K OHI; Y OKAMI; K MAEDA; H UMEZAWA
Journal:  J Antibiot (Tokyo)       Date:  1962-01       Impact factor: 2.649

4.  High-Resolution Structure of ClpC1-Rufomycin and Ligand Binding Studies Provide a Framework to Design and Optimize Anti-Tuberculosis Leads.

Authors:  Nina M Wolf; Hyun Lee; Mary P Choules; Guido F Pauli; Rasika Phansalkar; Jeffrey R Anderson; Wei Gao; Jinhong Ren; Bernard D Santarsiero; Hanki Lee; Jinhua Cheng; Ying-Yu Jin; Ngoc Anh Ho; Nguyen Minh Duc; Joo-Won Suh; Celerino Abad-Zapatero; Sanghyun Cho
Journal:  ACS Infect Dis       Date:  2019-05-03       Impact factor: 5.084

5.  THE STRUCTURES OF ILAMYCIN AND ILAMYCIN B2.

Authors:  T TAKITA; H NAGANAWA; K MAEDA; H UMEZAWA
Journal:  J Antibiot (Tokyo)       Date:  1964-05       Impact factor: 2.649

6.  THE AMINO ACID SEQUENCE OF ILAMYCIN AND ILAMYCIN B.

Authors:  T TAKITA
Journal:  J Antibiot (Tokyo)       Date:  1963-09       Impact factor: 2.649

7.  Residual Complexity Does Impact Organic Chemistry and Drug Discovery: The Case of Rufomyazine and Rufomycin.

Authors:  Mary P Choules; Larry L Klein; David C Lankin; James B McAlpine; Sang-Hyun Cho; Jinhua Cheng; Hanki Lee; Joo-Won Suh; Birgit U Jaki; Scott G Franzblau; Guido F Pauli
Journal:  J Org Chem       Date:  2018-05-24       Impact factor: 4.354

8.  Ilamycin C induces apoptosis and inhibits migration and invasion in triple-negative breast cancer by suppressing IL-6/STAT3 pathway.

Authors:  Qing Xie; Zhijie Yang; Xuanmei Huang; Zikang Zhang; Jiangbin Li; Jianhua Ju; Hua Zhang; Junying Ma
Journal:  J Hematol Oncol       Date:  2019-06-11       Impact factor: 17.388

9.  Biosynthesis of ilamycins featuring unusual building blocks and engineered production of enhanced anti-tuberculosis agents.

Authors:  Junying Ma; Hongbo Huang; Yunchang Xie; Zhiyong Liu; Jin Zhao; Chunyan Zhang; Yanxi Jia; Yun Zhang; Hua Zhang; Tianyu Zhang; Jianhua Ju
Journal:  Nat Commun       Date:  2017-08-30       Impact factor: 14.919

10.  Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus.

Authors:  Mary P Choules; Nina M Wolf; Hyun Lee; Jeffrey R Anderson; Edyta M Grzelak; Yuehong Wang; Rui Ma; Wei Gao; James B McAlpine; Ying-Yu Jin; Jinhua Cheng; Hanki Lee; Joo-Won Suh; Nguyen Minh Duc; Seungwha Paik; Jin Ho Choe; Eun-Kyeong Jo; Chulhun L Chang; Jong Seok Lee; Birgit U Jaki; Guido F Pauli; Scott G Franzblau; Sanghyun Cho
Journal:  Antimicrob Agents Chemother       Date:  2019-02-26       Impact factor: 5.191

View more
  1 in total

Review 1.  Marine Cyclic Peptides: Antimicrobial Activity and Synthetic Strategies.

Authors:  Ricardo Ribeiro; Eugénia Pinto; Carla Fernandes; Emília Sousa
Journal:  Mar Drugs       Date:  2022-06-15       Impact factor: 6.085

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.